<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374399</url>
  </required_header>
  <id_info>
    <org_study_id>DJCLS R 10/42pf</org_study_id>
    <nct_id>NCT01374399</nct_id>
  </id_info>
  <brief_title>Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA)</brief_title>
  <acronym>PETRA</acronym>
  <official_title>Effects of an One-year Physical Exercise Intervention on Prognosis, Side-effects and Complications After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PETRA-Study is a randomized, controlled trial and designed to examine the effects of an
      one-year physical exercise intervention on prognosis, side-effects and complications after
      allogeneic stem cell transplantation.

      The exercise intervention includes both, resistance and endurance training. Patients assigned
      to the control group perform a relaxation program (progressive muscle relaxation - Jacobsen)
      and have the same frequency of social contact.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>admission to hospital for allo-HSCT, discharge from hospital (expected average of 4 to 5 weeks after admission), day 100, day 180, day 270 and day 365 post transplanation</time_frame>
    <description>measured by the Multidimensional Fatique Inventory (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>admission to hospital for allo-HSCT, discharge from hospital (expected average of 4 to 5 weeks after admission), day 100, day 180, day 270 and day 365 post transplanation</time_frame>
    <description>mesured by the European Organistion for Research and Treatment of Cancer questionnaire including the high dose chemotherapy module (EORTC-QLQ-C30/HDC-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin, Leukocytes, Thrombocytes</measure>
    <time_frame>during hospitalisation for allo-HSCT (expected average 4-5 weeks), day 100, day 180, day 270, day 365 post transplantation</time_frame>
    <description>Hematological and immunological reconstitution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects (Infections, GvHD, Depression, Distress)</measure>
    <time_frame>during hospitalisation for allo-HSCT (expected average 4-5 weeks), day 100, day 180, day 270, day 365 post transplantation</time_frame>
    <description>Depression mesured by &quot;Allgemeine Depressionskala&quot; (ADS, the German version of the Center for Epidemiological Studies Depression Scale (CES-D)) Distress mesures by the NCCN Distress Thermometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to exercise protocol</measure>
    <time_frame>one year</time_frame>
    <description>Fesability of an one-year exercise intervention after allogeneic HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscular strength</measure>
    <time_frame>admission to hospital for allo-HSCT, discharge from hospital (expected average of 4 to 5 weeks after admission), day 100, day 180, day 270 and day 365 post transplanation</time_frame>
    <description>measured at the IsoMed2000 and/or Handheld Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiorespiratory fitness</measure>
    <time_frame>admission to hospital for allo-HSCT, discharge from hospital (expected average of 4 to 5 weeks after admission), day 100, day 180, day 270 and day 365 post transplanation</time_frame>
    <description>measured by ergospirometry (VO2max) and/or 6 Minutes Walk Test (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6, IL-4, IL-8, IL-10, IL-1ra, TNF-alpha, Prostaglandin</measure>
    <time_frame>admission to hospital for allo-HSCT, discharge from hospital (expected average of 4 to 5 weeks after admission), day 100, day 180, day 270 and day 365 post transplanation</time_frame>
    <description>Biomarker in blood and urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median survival, non-relapse mortality</measure>
    <time_frame>admission to hospital until 2 years after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>resistance and endurance exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>relaxation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise and relaxation</intervention_name>
    <description>resistance and endurance exercise, 3-5 times per week</description>
    <arm_group_label>resistance and endurance exercise</arm_group_label>
    <arm_group_label>relaxation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical indication: allogeneic stem cell transplantation

        Exclusion Criteria:

          -  Orthopeadic limitations that hamper the exercise intervention

          -  Osseous degenerations that have an improved fracture risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bohus, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Wiskemann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Tumor Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dreger Peter, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Cancer Research Center</name>
      <address>
        <city>Heidleberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>exercise</keyword>
  <keyword>survival</keyword>
  <keyword>fatigue</keyword>
  <keyword>quality of life</keyword>
  <keyword>cancer</keyword>
  <keyword>physical performance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

